Pharma Focus Asia


Manufacturing & Processing - Serving India and Beyond

Venus Remedies,

Having gained a h4 foothold in India\'s domestic sector, one Haryana-based company specialising in super speciality injectable drugs is working towards expanding its place in the world pharmaceuticals market.

Established in 1991, Venus Remedies Limited is a wholly Indian owned company, recognised as one of the most dynamic growth-and result-oriented companies in India. Its range of super speciality injectables covers the areas of:

  • Anti-cancer
  • Carbapenem
  • Chephalosporin
  • Over the counter (OTC) pharma

Technical Base

Venus' strength lies in its in-house R&D department, which boasts a panel of technical experts who are dedicated to the creation of new products in the therapeutic areas of FDCs and NSAIDs. The department has filed five patent applications for in-house research projects:

  • Treatment and control of severe infections including cystis fibrosis
  • Composition for combating beta-lactum medicated antibiotic resistance using betalactamase inhibitors useful for injection
  • Antibiotic combinations for providing total solution to the treatment of infections
  • Non-aqueous liquid parenteral NSAID formulation
  • Parenteral combination therapy for infective conditions with drug resistance bacterium

New Projects

Venus has created history with the launch of a single new formulation for generating a blockbuster in a short span of time. Other exciting projects the R&D department are working on include:

  • Drug delivery systems. Developing technology for manufacturing drugs in injectable and oral forms.
  • Fixed dose combinations. The development of more effective formulations by combining two or more APIs for an improved formulation with the effectiveness of both APIs and shorter treatment spans due to improved efficacy.

Venus' four dedicated state-of-the-art manufacturing facilities operate to the standards of US FDA and UK MHRA, and it is in the process of seeking international approval. The facilities comprise:

  • Anti-cancer injectable
  • Anti-cancer lypholised injectable
  • Carbapenem
  • Chephalosporin

Building the Future

Venus was first set up as a manufacturer of IV fluids. In 1994, it became a public limited company and expanded its operations to produce liquid vials, ampoules and dry powder injectables, followed by antibiotics, antihistamines and oncology drugs.

Venus has a h3 share in India's domestic pharmaceutical market, having supplied IV fluids to the northern India states, as well as to governmental institutions of Kerala, Karnataka and Haryana. The company's markets are not limited to India: it exports drugs to Nepal, Ukraine and Yemen. Venus clients include: Panacea Biotech, Sanat Products, Elder Pharmaceuticals, Jagsonpal Pharmaceuticals, Samarth Pharma, Ipca Laboratories and Lyka BDR Pharma.

Venus is keen to expand its global business and seeks partners for custom manufacturing, contract research, strategic marketing tie-ups, collaborations and joint ventures to further strengthen and consolidate its marketing alliances and manufacturing base. The company's strengths lie in the manufacture of sophisticated, super speciality products with timely deliveries, and it is constantly striving to deliver quality and satisfaction in the shortest time.

Venus Remedies' key strengths include

  • Over 15 years of experience
  • One of the fastest growing pharma firms in northern India
  • Quality products at affordable prices
  • Delivery to international standards
  • Skilled and trained professionals
  • WHO GMP accreditation

Author Bio

Venus Remedies

Venus Remedies

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024